Diagnostic 2-MHz frequency TCD ultrasound is a safe, bedside, repeatable and fast method that can diagnose arterial occlusion, continuously monitor recanalization and may be therapeutic in the setting of thrombolysis. A phase II study carried out within our previous SPOTRIAS grant demonstrated that stroke patients who received 2 hours of continuous TCD ultrasound in addition to rt-PA were significantly more likely to achieve complete recanalization compared to rt-PA alone with no increased risk of brain hemorrhage. Although TCD ultrasound improves recanalization, a definitive efficacy trial aimed at demonstrating improved patient outcomes would require more than 500 patients. To date, only operator-dependent hand-held devices have been shown to be safe and possibly effective. Unfortunately, the lack of widespread availability of trained personnel has limited its application. Development of an operator-independent TCD system would solve this problem and improve enrollment into ultrasound-enhanced stroke clinical trials. Through previous SPOTRIAS funding, such a device was developed at the University of Texas-Houston. The primary specific aim for this pilot phase l/ll study is to determine the safety of a novel, external Hands-Free transcranial Doppler ultrasound system. Importantly, since the Hands-Free TCD ultrasound system will not exceed current energy output standards of FDA approved diagnostic equipment, safety concerns are not anticipated yet will be carefully monitored and evaluated in three distinct groups. Safety and tolerability of the new Hands-Free TCD system, which also uses 2-MHz frequency ultrasound energy, will first be established in healthy volunteers. Safety in these healthy participants will be determined by detailed neurological exams and pre- and post-ultrasound brain MRIs. Next, safety of the device will be evaluated in two different sets of acute ischemic stroke patients: 0-3 hour patients treated with standard IV rt-PA and 3-6 hour non-lytic, image-selected patients treated with sonolysis (ultrasound + microbubbles). Safety in these stroke patients will be measured by incidence of symptomatic intracerebral hemorrhage and adverse events. Our primary hypothesis is that replacing conventional TCD ultrasound hand-held technology with a Hands-Free system will be safe in healthy volunteers as well as acute ischemic stroke patients. Our secondary hypothesis is that Hands-Free TCD will display similar recanalization and early clinical recovery rates compared to available historical diagnostic TCD ultrasound controls exposed to conventional, FDA-approved TCD technology. Data generated during this study will evaluate the safety of replacing an operator-dependent TCD device with an operator-independent system. Our long-term objective is to provide the widespread availability of ultrasoundenhanced thrombolysis which would significantly improve enrollment into ultrasound-stroke trials in order to establish effectiveness of this new treatment. If superior efficacy is established by combining rt-PA and Hands- Free TCD ultrasound, thousands more stroke patients could benefit and recover from their disabling disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS044227-09
Application #
8266883
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
9
Fiscal Year
2011
Total Cost
$210,884
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Type
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Berekashvili, Ketevan; Soomro, Jazba; Shen, Loren et al. (2018) Safety and Feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study). J Stroke Cerebrovasc Dis 27:3647-3651
Cai, Chunyan; Rahbar, Mohammad H; Hossain, Md Monir et al. (2017) A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research. Contemp Clin Trials Commun 7:11-17
Barreto, Andrew D; Ford, Gary A; Shen, Loren et al. (2017) Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke 48:1608-1616
Ifejika, Nneka Lotea; Noser, Elizabeth Anne; Grotta, James C et al. (2016) Swipe out Stroke: Feasibility and efficacy of using a smart-phone based mobile application to improve compliance with weight loss in obese minority stroke patients and their carers. Int J Stroke 11:593-603
Lyden, Patrick; Hemmen, Thomas; Grotta, James et al. (2016) Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2). Stroke 47:2888-2895
McDonald, Mark M; Wetzel, Jeremy; Fraser, Stuart et al. (2016) Thrombelastography does not predict clinical response to rtPA for acute ischemic stroke. J Thromb Thrombolysis 41:505-10
Vahidy, F S; Rahbar, M H; Lal, A P et al. (2015) Patient refusal of thrombolytic therapy for suspected acute ischemic stroke. Int J Stroke 10:882-6
Schlick, Konrad H; Hemmen, Thomas M; Lyden, Patrick D (2015) Seizures and Meperidine: Overstated and Underutilized. Ther Hypothermia Temp Manag 5:223-7
Ifejika, Nneka L; Vahidy, Farhaan; Aramburo-Maldonado, Linda A et al. (2015) Acute Intravenous Tissue Plasminogen Activator Therapy does not Impact Community Discharge after Inpatient Rehabilitation. Int J Neurorehabil 2:
Huang, Richard S P; McDonald, Mark M; Wetzel, Jeremy S et al. (2015) Clot Strength as Measured by Thrombelastography Correlates with Platelet Reactivity in Stroke Patients. Ann Clin Lab Sci 45:301-7

Showing the most recent 10 out of 72 publications